Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Hubeaux
S. Hubeaux
Hoffmann-La Roche
Ocrelizumab
Internal medicine
disability progression
Psychology
Anesthesia
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
2019
Journal of Neurology, Neurosurgery, and Psychiatry
Gavin Giovannoni
Stephen L. Hauser
Bruno Brochet
Xavier Montalban
Robert T. Naismith
Jerry S. Wolinsky
S. Hubeaux
Lahar Mehta
Fabian Model
Ludwig Kappos
Show All
Source
Cite
Save
Citations (0)
P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
2019
Clinical Neurophysiology
Stephen L. Hauser
H.-P. Hartung
Bruno Brochet
Xavier Montalban
Robert T. Naismith
Jerry S. Wolinsky
M. Manfrini
M. Garas
Fabian Model
S. Hubeaux
Ludwig Kappos
Show All
Source
Cite
Save
Citations (0)
P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
2019
Clinical Neurophysiology
Jerry S. Wolinsky
H.-P. Hartung
Bruno Brochet
Xavier Montalban
Robert T. Naismith
M. Manfrini
M. Garas
Fabian Model
S. Hubeaux
Ludwig Kappos
Stephen L. Hauser
Show All
Source
Cite
Save
Citations (0)
1